Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.
Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]